Synthesis and antibacterial activity of some derivatives of tolypomycinone. Relationship between structure and activity in ansamycins

The relationship between just world belief and wellbeing, cheating behaviors, and academic work behaviors during COVID 19 among university students

Is the belief in a just world among students also stable under COVID-19? To answer this question, a study was conducted with university students from Germany (n = 291). The aim of the study was to analyze the predictive performance of the personal belief in a just world (PBJW) on students' life satisfaction and academic cheating and to take into account important mediators from the university context such as fellow student justice, lecturer justice, and procrastination. Derived from existing research, university students with a stronger PBJW should be more satisfied with their lives and cheat less than those with a weaker PBJW. The results support the hypothesized direct effects of PBJW on life satisfaction. Procrastination additionally mediated the effect of PBJW on life satisfaction. The level of PBJW predicted academic cheating only indirectly. The mediators procrastination and lecturer justice were crucial here. The results persisted when gender, learning, time to exam, socially desirable responding, general BJW, and self-efficacy were controlled. The findings were discussed in relation to the stressful situation caused by COVID-19. A reflection on the adaptive function of PBJW as a resource and relevant situation-specific mediators for university research and practice followed.

Rifamycins--obstacles and opportunities

With nearly one-third of the global population infected by Mycobacterium tuberculosis, TB remains a major cause of death (1.7 million in 2006). TB is particularly severe in parts of Asia and Africa where it is often present in AIDS patients. Difficulties in treatment are exacerbated by the 6-9 month treatment times and numerous side effects. There is significant concern about the multi-drug-resistant (MDR) strains of TB (0.5 million MDR-TB cases worldwide in 2006). The rifamycins, long considered a mainstay of TB treatment, were a tremendous breakthrough when they were developed in the 1960's. While the rifamycins display many admirable qualities, they still have a number of shortfalls including: rapid selection of resistant mutants, hepatotoxicity, a flu-like syndrome (especially at higher doses), potent induction of cytochromes P450 (CYP) and inhibition of hepatic transporters. This review of the state-of-the-art regarding rifamycins suggests that it is quite possible to devise improved rifamycin analogs. Studies showing the potential of shortening the duration of treatment if higher doses could be tolerated, also suggest that more potent (or less toxic) rifamycin analogs might accomplish the same end. The improved activity against rifampin-resistant strains by some analogs promises that further work in this area, especially if the information from co-crystal structures with RNA polymerase is applied, should lead to even better analogs. The extensive drug-drug interactions seen with rifampin have already been somewhat ameliorated with rifabutin and rifalazil, and the use of a CYP-induction screening assay should serve to efficiently identify even better analogs. The toxicity due to the flu-like syndrome is an issue that needs effective resolution, particularly for analogs in the rifalazil class. It would be of interest to profile rifalazil and analogs in relation to rifampin, rifapentine, and rifabutin in a variety of screens, particularly those that might relate to hypersensitivity or immunomodulatory processes.